文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients.

作者信息

Yan Xiu-Juan, Li Wen-Ting, Chen Xin, Wang Er-Man, Liu Qing, Qiu Hong-Yi, Cao Zhi-Jun, Chen Sheng-Liang

机构信息

Xiu-Juan Yan, Wen-Ting Li, Xin Chen, Er-Man Wang, Qing Liu, Hong-Yi Qiu, Zhi-Jun Cao, Sheng-Liang Chen, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai 200001, China.

出版信息

World J Gastroenterol. 2015 Apr 21;21(15):4652-9. doi: 10.3748/wjg.v21.i15.4652.


DOI:10.3748/wjg.v21.i15.4652
PMID:25914475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4402313/
Abstract

AIM: To explore whether clinician-patient communication affects adherence to psychoactive drugs in functional dyspepsia (FD) patients with psychological symptoms. METHODS: A total of 262 FD patients with psychological symptoms were randomly assigned to four groups. The patients in Groups 1-3 were given flupentixol-melitracen (FM) plus omeprazole treatment. Those in Group 1 received explanations of both the psychological and gastrointestinal (GI) mechanisms of the generation of FD symptoms and the effects of FM. In Group 2, only the psychological mechanisms were emphasized. The patients in Group 3 were not given an explanation for the prescription of FM. Those in Group 4 were given omeprazole alone. The primary endpoints of this study were compliance rate and compliance index to FM in Groups 1-3. Survival analyses were also conducted. The secondary end points were dyspepsia and psychological symptom improvement in Groups 1-4. The correlations between the compliance indices and the reductions in dyspepsia and psychological symptom scores were also evaluated in Groups 1-3. RESULTS: After 8 wk of treatment, the compliance rates were 67.7% in Group 1, 42.4% in Group 2 and 47.7% in Group 3 (Group 1 vs Group 2, P = 0.006; Group 1 vs Group 3, P = 0.033). The compliance index (Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.024) with the FM regimen was significantly higher in Group 1 than in Groups 2 and 3. The survival analysis revealed that the patients in Group 1 exhibited a significantly higher compliance rate than Groups 2 and 3 (Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.018). The improvement in dyspepsia (Group 1 vs Group 2, P < 0.05; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01) and psychological symptom scores (anxiety: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01; depression: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.01; Group 1 vs Group 4, P < 0.01) in Group 1 were greater than those in Groups 2-4. The compliance indices were positively correlated with the reduction in symptom scores in Groups 1-3. CONCLUSION: Appropriate clinician-patient communication regarding the reasons for prescribing psychoactive drugs that emphasizes both the psychological and GI mechanisms might improve adherence to FM in patients with FD.

摘要

相似文献

[1]
Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients.

World J Gastroenterol. 2015-4-21

[2]
Benefit of small dose antidepressants for functional dyspepsia: Experience from a tertiary center in eastern China.

Medicine (Baltimore). 2019-10

[3]
Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.

Medicine (Baltimore). 2019-1

[4]
Changes in patients' symptoms and gastric emptying after Helicobacter pylori treatment.

World J Gastroenterol. 2016-5-14

[5]
Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia.

Aliment Pharmacol Ther. 2008-6-1

[6]
Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients.

Am J Gastroenterol. 2015-10

[7]
Xiaoyao pill for treatment of functional dyspepsia in perimenopausal women with depression.

World J Gastroenterol. 2014-11-28

[8]
Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.

J Gastroenterol Hepatol. 2014-6

[9]
Acupuncture effectiveness as a complementary therapy in functional dyspepsia patients.

Arq Gastroenterol. 2013

[10]
Daily Short Message Service Reminders Increase Treatment Compliance and Efficacy in Outpatients with Functional Dyspepsia: a Prospective Randomized Controlled Trial.

J Gen Intern Med. 2020-10

引用本文的文献

[1]
Long-Term Effects of Low-Dose Aspirin on Gastrointestinal Symptoms and Bleeding Complications in Patients with Type 2 Diabetes.

Am J Cardiovasc Drugs. 2025-1

[2]
Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial.

Front Psychiatry. 2022-12-8

[3]
Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial.

Front Med (Lausanne). 2022-7-22

[4]
Improving Clinician-Patient Communication Alleviates Stigma in Patients With Functional Dyspepsia Receiving Antidepressant Treatment.

J Neurogastroenterol Motil. 2022-1-30

[5]
Comparative Efficacy of Antidepressants for Symptoms Remission of Gastroesophageal Reflux: A Bayesian Network Meta-analysis of Randomized Controlled Trials.

Turk J Gastroenterol. 2021-10

[6]
A Qualitative Exploration to Understand Hospitalists' Attitude Toward the Patient Experience Scoring System.

J Patient Exp. 2020-12

[7]
Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.

Medicine (Baltimore). 2019-1

[8]
Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.

Aliment Pharmacol Ther. 2018-9-7

本文引用的文献

[1]
Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Gastroenterol Hepatol (N Y). 2006-9

[2]
The role of psychosocial factors and psychiatric disorders in functional dyspepsia.

Nat Rev Gastroenterol Hepatol. 2013-1-29

[3]
Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases.

J Gastroenterol. 2012-12-20

[4]
Depressive symptoms in people with chronic physical conditions: prevalence and risk factors in a Hong Kong community sample.

BMC Psychiatry. 2012-11-14

[5]
Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study.

Aliment Pharmacol Ther. 2012-9-8

[6]
The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review.

BMC Psychiatry. 2012-7-24

[7]
Review article: current treatment options and management of functional dyspepsia.

Aliment Pharmacol Ther. 2012-5-16

[8]
Psychological Co-morbidity in Functional Gastrointestinal Disorders: Epidemiology, Mechanisms and Management.

J Neurogastroenterol Motil. 2012-1-16

[9]
Role of serotonin in gastrointestinal physiology and pathology.

Minerva Endocrinol. 2011-12

[10]
The compliance with antidepressants in general practice.

J Psychopharmacol. 1994-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索